Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Ectopic expression of LMO2 occurs in approximately 45% of T-lineage acute lymphoblastic leukemias (T-ALL), sometimes in association with chromosomal translocations. Recently, a lymphoproliferative disorder developed in two participants in a gene therapy trial due to LMO2 activation via integration of the retroviral vector. To investigate these regulatory disruptions, we analyzed the promoter region and identified a tissue-specific repressor. The fragment containing this element could also produce tissue-specific suppression of transcription from the SV40 promoter. This suppression involves histone acetylation which can be relieved with Trichostatin A (TSA). The negative element is in a region consistently removed from LMO2 in the known chromosomal translocations.

Original publication




Journal article


Leuk Res

Publication Date





89 - 97


Adaptor Proteins, Signal Transducing, Base Sequence, Consensus Sequence, DNA-Binding Proteins, Histone Deacetylases, Humans, Hydroxamic Acids, Jurkat Cells, K562 Cells, LIM Domain Proteins, Leukemia, Metalloproteins, Molecular Sequence Data, Organ Specificity, Proto-Oncogene Proteins, Proto-Oncogenes, Regulatory Sequences, Nucleic Acid, Transcription, Genetic, Transfection